COMP <GO>
OVID vs CBIO // RETURN ON INVESTED CAPITAL (ROIC)
Ovid Therapeutics Inc. (NASDAQ) VS. Crescent Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: OVID 4
— CBIO 2
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: OVID
LAST: $2.54 (-0.78%) • MKT CAP: $496.1M
roic
-28.50%
LAST: $13.48 (-4.19%) • MKT CAP: $500.7M
roic
-35.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OVID VS. CBIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OVID | CBIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -28.50% | -35.00% | +6.50 | OVID | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.67% | -13.86% | +6.19 | OVID | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 1.40% | -61.40 | CBIO | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.46 | 6.36 | +5.10 | OVID | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.8 | 46.5 | +9.30 | OVID | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $496.1M | $500.7M | -$4.6M | CBIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OVID REV | CBIO REV | OVID GROSS % | CBIO GROSS % | OVID FCF | CBIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $7.3M | $10.8M | — | — | -$38.3M | -$72.5M |
| FY 2024 | $566.0K | $0 | — | — | -$56.0M | -$31.1M |
| FY 2023 | $392.0K | $0 | — | — | -$45.8M | -$34.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OVID // BETA —
CBIO // BETA —